retatrutide type 2 diabetes trial results 2024 2025 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Therapeutic Potential of GLP-1 Type:Paperback Dietary Concern_High Protein (15g+)

retatrutide type 2 diabetes trial results 2024 2025 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Therapeutic Potential of GLP-1 Type:Paperback Dietary Concern_High Protein (15g+)

Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications | Cardiovascular Drugs and Therapy | Springer Nature Link

For patients exploring GLP-1 treatment options, understanding the full cost structure—including consultation fees, medication formulation type, and whether genetic or biomarker data might inform dosing—is essential for making informed decisions

Dietary Concern_High Protein (15g+)

Type:Paperback

Swelling: Swelling of the face, lips, tongue, or throat is a sign of a severe allergic reaction